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Objective: We describe our initial experience with the use of the TriVascular Ovation endograft system for the
treatment of abdominal aortic aneurysms (AAA).
Methods: We retrospectively reviewed data from patients treated for AAA using the Ovation endograft at two
institutions from January 2011 to September 2012. Main outcomes included primary success, survival, complications,
and device-related events. The mean follow-up period was 10 months (range 1–22 months).
Results: Thirty-seven patients (male: 95%, mean age: 76 yr) were treated for AAA (mean diameter: 54 mm) with the
Ovation endograft. Local or regional anesthesia was used in 86.5% of cases. Percutaneous access was utilized in
73% of cases. Primary success was 89.2% (33/37). Four adjunctive procedures were required including two distal
extensions (type 1b endoleak and iliac limb disconnection resulting in type III endoleak) and two bypass surgeries
(limb graft occlusion and gate cannulation failure). No deaths or major complications were reported during the
procedure or in follow-up. No type I, III, or IV endoleak, AAA enlargement, AAA rupture, stent fracture, migration, or
endovascular or surgical reintervention were reported during the follow-up period. Type II endoleak was observed
in two patients. Asymptomatic narrowing of both iliac limbs was observed in one patient at 6 months.
Conclusions: Our initial experience with the Ovation endograft demonstrated encouraging results in patients
with AAA.
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The first endovascular repair of an abdominal aortic
aneurysm (AAA) was performed in 1990 by Dr. Parodi
[1], who implanted a large straight endograft into the ab-
dominal aorta. Limitations of the use of a similar device
soon became evident and new self-expandable materials
and bifurcated stent-grafts, which had a smaller caliber
than previous generations, rapidly became available. The
latest generation of ultra-low profile endografts currently
allows the treatment of AAAs in patients who have previ-
ously been excluded because of challenging aortic anat-
omies and small access vessels.* Correspondence: danymazzak83@libero.it
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unless otherwise stated.However, some have expressed concern that reducing the
profile of a stent graft may compromise sealing. The search
for an endograft with a smaller profile with no compromise
on performance and durability of the device remains a
therapeutic challenge. After having received the CE Mark
on September 17th 2010, the low-profile TriVascular
Ovation system (14 F) has been recently introduced also
to our institutions for use in selected patients with rela-
tively challenging necks or smaller iliac vessels. The
purpose of this study was to retrospectively review our
early experience with this novel stent graft.Methods
Ethics
The research described in this manuscript was approved
by the Institutional Review Board at each respective in-
stitution and was conducted per the guidance set forth
in the Declaration of Helsinki.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The Ovation Trivascular graft.
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We retrospectively reviewed data of all patients who were
treated for AAA using the Ovation endograft system from
January 2011 to September 2012 in our two centres.
Patients who meet specific anatomic criteria of both
proximal and distal landing zone (non-aneurysmal prox-
imal aortic neck length of at least 7 mm, proximal neck lu-
minal diameter between 16 and 30 mm, non-aneurysmal
distal iliac artery length of at least 10 mm, distal iliac lu-
minal diameters between 8 and 20 mm, possibility to pre-
serve patency in at least one hypogastric artery, distance
from the most distal renal artery to most superior internal
iliac artery measurement of at least 13 cm) were considered
suitable for the implantation of the Ovation Abdominal
Stent Graft.
One patient was treated outside the IFU of the Ovation
Stent Graft, with a pre-planned “chimney-technique” be-
cause of AAA involving both renal arteries. Due to small
iliac access, however, it was not possible to treat the pa-
tient using a different type of endograft.
Patients with a dissecting or acutely ruptured aneurysm
were excluded, as well as patients with history of connective
tissue disease (e.g., Marfan's or Ehler's-Danlos syndrome)
or with a known allergy or intolerance to polytetrafluor-
ethylene (PTFE), PEG-based polymers, fluorinated ethylene
propylene (FEP) or nitinol.
After treatment all patients were discharged on anti-
platelet therapy (either ASA 100 mg daily or Clopidogrel
75 mg daily all lifelong) unless they were already on anti-
coagulant therapy for preoperative comorbidities.
Ovation stent graft
The Ovation Abdominal Stent Graft (TriVascular, Inc.,
Santa Rosa, CA, USA) is a modular two-docking limb
device system with the aortic body delivered via a flex-
ible hydrophilic-coated 14 Fr OD catheter, as well as the
contralateral limb. The aortic body is comprised of a low
permeability PTFE graft and a suprarenal nitinol stent
with integral anchors to achieve active fixation to the
aortic wall. The iliac limbs are made of a low permeabil-
ity PTFE graft with an external scaffold of nitinol stents.
The Ovation system has ring-shaped channels (Figure 1)
that are injected with a polyethylene glycol [PEG]-based
polymer, which expands the endograft against the aorta
to create a proximal seal.
The polymer is radiopaque, allowing the filling of the
graft to be observed under fluoroscopy. Once the main
body of the graft is positioned and opened, the polymer
is prepared on the operating table, and mixed in a syr-
inge that will be joined to the graft introducer. The syr-
inge itself is joined to an autoinjector which pushes the
polymer through the ring-shaped channels in 20 minutes,
during which it is possible to complete the placement of
the contralateral iliac extension. When the time of thepolymer’s filling is elapsed, the syringe and the autoinjec-
tor are removed together and it is possible to place the
eventual ipsilateral iliac extension.
Because of the ultra-low profile, the Ovation system
can be used in patients with iliac or femoral artery access
of less than 7 mm. The Ovation device is contraindicated
in patients who have allergies to the device materials, as
well as in patients who are unable to undergo the neces-
sary preoperative and postoperative imaging studies.Outcomes
Patient records were reviewed for demographics, medical
history, and aortoiliac morphology via computed tomog-
raphy angiography. Procedural data included fluoroscopy
Table 1 Patients’ characteristics and anatomical data
n = 37
Male Sex 35 (94.6%)





Current or previous smoke 19 (51.3%)
COPD 13 (35.1%)







Anatomical data (Mean ± SD), mm
Proximal aortic neck diameter 25.9 ± 0.8
Proximal aortic neck lenght 18 ± 2.1
Proximal aortic neck angulation 52.2° ± 4.2°
Distal aortic neck diameter 27.7 ± 0.4
Distal aortic neck lenght 24 ± 1.2
Proximal RCIA 12.3 ± 0.2
Distal RCIA 14.2 ± 0.5
Proximal LCIA 14.2 ± 0.4
Distal LCIA 13.9 ± 0.7
Smaller EIA 8.1 ± 0.7
Sac diameter (range) 5.4 (5.0-8.5)
Aortic length 82 (58–122)
PSA = Pseudoaneurysm.
COPD = Chronic Obstructive Pulmonary Disease.
CABG = Coronary Artery Bypass Grafting.
RCIA = Right Common Iliac Artery.
LCIA = Left Common Iliac Artery.
EIA = External Iliac Artery.
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medium, blood loss, and complications. Follow-up data
were obtained from outpatient visits and CT scan or du-
plex scans. Imaging was performed every 3 months during
the first year after the operation and annually thereafter
using mainly duplex scans. A CT scan was regularly per-
formed at 1 year and in any case of inconclusive duplex
scan (i.e. hostile abdomen) or finding of sac enlargement/
graft occlusion/stenosis/endoleaks at duplex scan. Out-
comes were analyzed to evaluate primary success, survival,
complications, and device-related events. Primary success
was defined as successful access, delivery, and implant of
the endograft with absence of surgical conversion, mortal-
ity, type I or III endoleak, or graft limb obstruction.
Data analysis
Statistical analysis was performed using JMP® 5.1.2 (SAS
Institute, Inc., Cary, NC, USA). Continuous variables are
reported as mean ± SD and categorical variables are pre-
sented as n (%). Logistic regression using the Wald stat-
istic was performed to identify predictors of adjunctive




Thirty-seven patients (35 males, mean age 76 years) with
AAA (mean 54 mm diameter) were treated with the
Ovation endograft. Primary AAA etiology was atheroscler-
otic and degenerative (n = 35) while 2 patients presented
with aortic pseudoaneurysm of proximal anastomosis from
previous AAA open surgery. The most common patient
comorbidities included current or previous smoking (51%),
chronic obstructive pulmonary disease (35%), and previous
coronary artery bypass grafting (32%). No patient pre-
sented with severe renal failure. Twenty nine percent of
treated aortic necks were shorter than 15 mm and 15%
were less than 10 mm in length. Twenty percent of pa-
tients treated had an access vessel less than 7 mm in diam-
eter, including a minimum diameter of 4.7 mm (Table 1).
Procedural data
Intraprocedural data are described in Table 2. All proce-
dures were performed by vascular surgeons in the oper-
ating theatre. Most (86.5%) procedures were performed
using either local or regional anesthesia. Endovascular
repair was performed via percutaneous bilateral femoral
access in 27 patients, while in the remaining 10 cases bi-
lateral surgical exposure of both common femoral arter-
ies was necessary.
An additional percutaneous brachial access was per-
formed in 2 patients in which a “Chimney Technique” was
used. In one of these cases, the AAA involved the origin of
both renal arteries while in the remaining case the chimneygraft was used as a bail-out technique, allowing a safe
proximal landing zone without covering the right renal
artery. In both patients, a Viabahn® covered stent was
advanced antegrade through brachial access. The prox-
imal rings of the Ovation graft were inflated while a bal-
loon was kept inflated within the covered stent.
All grafts were oversized less than 20%; in both cases
in which a “Chimney Technique” was used, the graft had
a 10% oversize.
Closure of the access site was obtained with manual
compression bilaterally in 2 out of 27 cases of percutan-
eous femoral access. A vascular closure device was used
in the remaining cases of percutaneous femoral access.




Local + conscious sedation 7 (18.9%)
General 5 (13.5%)
Vascular access
Percutaneous femoral 27 (73%)
Percutaneous brachial (additional) 2 (5.4%)
Surgical femoral 10 (27%)
Time of operation (min) 43.1 ± 3.2
Amount of contrast (cc) 28.3 ± 2.5
Fluoroscopy time (min) 11.3 ± 1.5
Blood loss (cc) 110 ± 16
Primary success 33 (89.2%)
Adjunctive procedure* 4 (10.8%)
Length of stay (days) 3.6 ± 0.9
30-day results
Death 0 (0%)




Major adverse events 0 (0%)
Endoleak type II 2 (5.4%)
Asintomatic narrowing of iliac limbs 1 (2.8%)
Thirty-day and long-term results.
*two distal extensions (type 1b endoleak and iliac limb disconnection resulting
in type III endoleak) and two bypass surgeries (limb graft occlusion and gate
cannulation failure).
Table 3 Logistic regression predicting risk of adjunctive
procedures from aortoiliac characteristics
ODDS RATIO 95%CI P
Proximal aortic neck diameter 12 2.36 - 24.17 .02
Proximal aortic neck length 0.82 0.21 – 1.80 .12
Distal aortic neck diameter 1.26 0.36 – 4.82 .08
Distal aortic neck lenght 2 0.73 – 5.16 .21
Proximal RCIA 0.42 0.01 – 2.23 .32
Distal RCIA 0.99 0.67 – 4.11 .69
Proximal LCIA 2.18 0.87 – 3.92 .23
Distal LCIA diameter 1.6 0.09 – 3.2 .40
Sac diameter 2.21 0.58 – 3.64 .28
Aortic length 1.12 0.77 – 2.14 .12
EIA diameter 0.90 0.42 – 1.23 .38
Nominal logistic fit, Wald effect test 1 DF. Significant P value in bold.
CI = Confidence Interval.
RCIA = Right Common Iliac Artery.
LCIA = Left Common Iliac Artery.
EIA = External Iliac Artery.
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patients required adjunctive procedures during the oper-
ation. In one case, given the twist of the device, which
opened incompletely at the gate, we were not able to
canulate the contralateral leg. Therefore, although a good
proximal seal had been obtained, a conical stent graft
(Talent, Medtronic) was placed, with an occluder at the
level of the left common iliac artery, and a femoro-
femoral right-to-left bypass was performed. In the second
case, intraoperative graft occlusion of the right leg required
an additional femoro-femoral left-to-right bypass. In the
third case, the device failed despite proper deployment with
enough overlap. Disconnection between the main body and
the left leg occurred, causing an intraprocedural type III
endoleak which was immediately corrected with a second
iliac extension. In the fourth case, a type Ib endoleak at
the end of the procedure required the placement of a
distal iliac extension.
No patient required a blood transfusion or ICU stay. No
access-related complication or post-implantation syndromewas reported. The risk of adjunctive procedures was higher
in patients with smaller proximal neck diameter (OR 12,
95% CI 2.36-24.17, P = .02) (Table 3), but it should be
noted that these complications usually are not correlated
to proximal neck diameter.
Safety and effectiveness outcomes
The mean follow-up period was 10 months (range 1–
22 months). No deaths or major complications were re-
ported during follow-up. No type I, III, or IV endoleaks,
AAA enlargement, AAA rupture, stent fracture, migra-
tion, or secondary endovascular procedure, or conver-
sion to open surgery were reported during the follow-up
period. An asymptomatic narrowing of both iliac limbs
was observed in one patient at 6 months (Figure 2),
which is still on follow-up. The patient is taking oral
anticoagulant for a permanent atrial fibrillation. There
was a type II endoleak from lumbar arteries in two patients
who are still under surveillance. Neither the former nor
the latter complications occurred in both patients who had
received the graft using the “Chimney” technique.
Discussion
Since Parodi’s initial experience [1], the need to have ap-
propriate vascular access to deliver the aortic stent graft
in EVAR has emerged as a main issue. As the endovas-
cular experience grew, it soon became clear that when
endovascular therapy was indicated for clinical criteria,
it was often not feasible for anatomical reasons. The
introduction of self-expandable materials permitted an
extension of the method even in those patients who pre-
sented with small iliac-femoral access. Nevertheless, in
the common practice, access site related complications
Figure 2 CT-angiography control at 6 months. The arrow
indicates the slight narrowing of the iliac legs of the graft.
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haematomas in case of percutaneous approaches. Reduced
access site complications and lower overall procedural
mortality rates after EVAR have been recently reported
with the use of new lower-profile endograft systems [2-5].
The benefits of lower-profile devices are obvious. Not
only is the risk of access site complications lower with
smaller profile systems, but more patients with smaller
access vessels can also be treated. However the downside
of reducing the profile is the possible loss of proximal
sealing, which can compromise the overall performanceFigure 3 How to improve the Ovation Trivascular graft: 1. shorter fre
ring; 4. strengthened distal part of the main body.and durability of the device. For this purpose, not only
were different anchoring systems introduced, but also
prostheses with large free-flow. The theoretical assump-
tion concerned the axiom that good sealing without mi-
gration meant absence of endoleak. It was realized that
this axiom was true in part and that even in presence of
graft migration sometimes there were no endoleaks.
The Ovation stent addresses these dual problems by
combining a large free-flow with hooks with an inflat-
able ring begins 10 mm below the top of the covered
part of the graft. The graft is fixed and the ring provides
sealing to the arterial wall. By eliminating the need for a
metallic endoframe entirely, the Ovation can keep a lower
profile while achieving a good proximal sealing and likely
a good durability over time.
In this sense our results are consistent with the pur-
pose of the endograft since in the long-term we have not
seen neither type I endoleaks nor graft migrations.
In our series, we observed some intraprocedural com-
plications, all of which were successfully corrected with
either a graft extension or fem-fem bypass surgery. On
one hand, the reduction of the profile allowed the treat-
ment of cases that would have been difficult or impractical
to treat with other devices. On the other side, the reduc-
tion of the prosthesic structure might have increased the
intraprocedural difficulties and also made cannulation of
the gate more difficult, which in a patient of our case
series led to a fem-fem bypass surgery.e-flow; 2. less stiff free-flow; 3. shorter sealing collar above the
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proximal neck diameter was small. We could not explain
the reason for this finding, as the complications observed
usually are not correlated to proximal neck diameter.
Moreover, the retrospective nature of our analysis and the
small number of cases limit the strength of this conclu-
sion. However, strengthening the distal part of the main
body would probably be useful to facilitate cannulation of
the gate and to avoid the shrinkage of the iliac legs, as ob-
served in a patient of our study. Moreover, as the real
proximal sealing is obtained through the polymer, the
prosthetic ring above the sealing collar could be elimi-
nated, improving the landing zone of the free-flow which
could be shortened and made less stiff (Figure 3).
Speculating on graft modifications is beyond the scope
of our study, however industries should address im-
provements of the graft considering real life experiences.
To some degree, the problems associated with cannu-
lation have been addressed by the Ovation PRIME, the
newest iteration of the endoprosthesis, which received
CE Mark in June, 2012. In this version of the device, the
contralateral leg is connected to the delivery system via
a trigger wire, which is designed to prevent the twisting
that caused the failure to cannulate described previously.
Albeit the experience is only at the beginning, the re-
sults reported in our series are encouraging, consistent
with those reported in the Ovation pre-market clinical
trial [6] in terms of aneurysm exclusion and prevention
of aortic rupture.
Metha et al. [7] recently published a prospective, mul-
ticenter, single-arm trial to evaluate the one-year results
about safety and effectiveness of the Ovation stent graft in
161 patients with AAAs. They reported a 30-day major
adverse event rate of 2.5%, while at 1 year, AAA-related
and all-cause mortality were 0.6% and 2.5%, respectively.
Similarly to our results, no stent graft migration, no AAA
rupture or type I, III, or IV endoleaks were reported in the
long term but type II endoleaks were identified in 34% of
patients and AAA-related secondary procedures were per-
formed in 10 patients (6.2%) for 6 endoleaks, 3 aortic main
body stenosis and 3 iliac limb stenosis or occlusion.
Similar outcomes are expected in UE post-marketing
study. Moreover, the ongoing prospective non-randomized
multi-center pre-market clinical trial [8] will probably build
further understanding on the use of this device and its dur-
ability over time.
Conclusions
Our initial experience with the Ovation endograft dem-
onstrated encouraging early and long-term results in pa-
tients with AAA in terms of safety and effectiveness.
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